(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 5.96% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Phibro Animal Health's revenue in 2025 is $1,296,215,000.On average, 3 Wall Street analysts forecast PAHC's revenue for 2026 to be $59,207,643,874, with the lowest PAHC revenue forecast at $58,983,290,353, and the highest PAHC revenue forecast at $59,518,333,979. On average, 3 Wall Street analysts forecast PAHC's revenue for 2027 to be $60,630,657,250, with the lowest PAHC revenue forecast at $60,206,594,643, and the highest PAHC revenue forecast at $60,998,621,343.
In 2028, PAHC is forecast to generate $62,586,768,638 in revenue, with the lowest revenue forecast at $62,539,303,783 and the highest revenue forecast at $62,644,002,093.